Virile.ai covers the latest artificial intelligence in medicine — genomics, imaging, and clinical decision support — written for practicing clinicians, not a consumer telehealth pitch.
Read the featured story
DeepMind’s newest genomics release is less a single model demo and more a catalog — precomputed effects across every possible single-letter DNA change.
Google DeepMind describes AlphaGenome Atlas as a platform with molecular predictions for about 9 billion single-nucleotide variants — every single-letter change possible in the human genome — plus an AlphaGenome Variant Impact (AVI) score that rolls coding and non-coding signals into one ranking clinicians and researchers can query.
Think of the clinical metaphor as a periodic-table-scale reference for genome letter combinations: not because DeepMind branded it that way, but because the atlas aims to make “every possible one-base change” look-upable rather than recomputed case by case. DeepMind notes the underlying AlphaGenome model is for research use and has not been designed or validated for direct clinical decision-making.
Editorial summary only. Always verify against primary sources and your institution’s evidence standards before changing practice.
Recent, real stories with outbound links.
DeepMind’s AlphaGenome paper in Nature (Jan 2026) details a unifying sequence model that takes up to 1 Mb of DNA and predicts thousands of molecular properties for variant-effect research — complementary to protein-focused tools like AlphaMissense.
Nature article → DeepMind explainer →FDA’s public AI-enabled device list remains the reference inventory. Industry coverage of the mid-2026 update put radiology at roughly three-quarters of cleared algorithms — useful context when a vendor pitch lands in your inbox.
FDA AI-enabled devices list → Radiology Business summary →Heartvue.ai announced FDA 510(k) clearance (K260811) for Heartvue.Proton, ML-assisted viewing and quantitative evaluation of cardiovascular MR — including volumes/EF and flow — with clinician review remaining in the loop, plus a Predetermined Change Control Plan.
Business Wire release →Cercare Medical received FDA 510(k) clearance for an AI brain-tumor segmentation module intended to semi-automate MRI contouring inside radiology workflows — including an on-premises deployment story aimed at health-system data governance requirements.
MPO coverage →Tools like AlphaGenome are positioned for research interpretation of variants; FDA-cleared imaging software is a different regulatory and workflow category. This site flags that split so headlines don’t get collapsed into “AI can diagnose.”
DeepMind research-use note →Each card points at a primary or reputable trade source. If a claim matters for patient care, read the paper, the FDA summary, and your local P&T / informatics process — not just the headline.
About this site →Virile.ai is an editorial front door for doctors and clinical leaders who need fast, sourced pointers to what changed in AI for medicine — without a prescription checkout or consumer men’s-health funnel.
Short cards on genomics, imaging, and clinical AI with outbound links.
Open the primary source before anything reaches a protocol or purchase committee.
Research models, cleared devices, and vendor marketing are labeled separately when we can.
Not medical advice. Not an FDA communication. Not affiliated with Google, DeepMind, the FDA, or the companies named in story cards.
This homepage replaces the previous consumer telehealth marketing page. Earlier edition retained for history. See the story archive.